Sign inJoin waitlistJoin the waitlist

DJ

Deepa Jeyakumar

Medical Director, Douglas Hospital Units 76 & 78 · University of California

Credentials: · · · ·

History

Douglas Hospital Units 76 & 78 · University of California
Present
University of California
Present
University of California
Present

Hematology and Medical Oncology
2013–2016
Stanford Medicine
2012–2013
Internal Medicine
2005–2008
Temple University
2001–2005

Research

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
The Lancet · 2021 · 704 citations
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine · 2024 · 235 citations
A sensitive, quantitative assay for human immunodeficiency virus type 1 integration
Journal of Virology · 2002 · 194 citations

Piyanuch Kongtim
12 papers
Stefan Ciurea
12 papers
SO
Susan O'Brien
11 papers
Gary Schiller
8 papers
Aaron Logan
7 papers
Dimitrios Tzachanis
7 papers
Daniel DeAngelo
6 papers
Kristen O'Dwyer
6 papers
Brian Jonas
5 papers
JP
Jae Park
5 papers
Maria Baer
5 papers
MW
Matthew Wieduwilt
5 papers

Clinical trials

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Principal investigator · Active not recruiting · Phase 2
University of California, Irvine
2020–2027
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027